Trial reportFrontiers in cellular and infection microbiology2022
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for
Trial report in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06292546 (The Effects of High-dose Dual Therapy Combined With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment), which is not on this map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of High-dose Dual Therapy Combined With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Trial
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Factors affecting dysbiosis of the gut microbiota in the elderly and the progress of interventions in traditional Chinese and Western medicine.Frontiers in cellular and infection microbiology · 2025Pooled it
- The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.Nutrition journal · 2025Trial
- Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.BMC gastroenterology · 2023Trial
- Gastric Microbiota Dysbiosis and Microbiome-Based Interventions in Chronic Atrophic Gastritis.Nutrients · 2026Review
- Evolution of Amoxicillin-Based Mono-Antibiotic Regimens forMicroorganisms · 2026Review
- The hidden cost of antibiotics: microbial dysbiosis-induced SCFA imbalance and its underlying mechanisms.Frontiers in immunology · 2026Review
- Review
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Review
- Metabolic Alterations of Short-Chain Organic Acids in the Elderly Link Antibiotic Exposure with the Risk for Depression.Metabolites · 2024Article
- The causality of gut microbiota on onset and progression of sepsis: a bi-directional Mendelian randomization analysis.Frontiers in immunology · 2024Article
- Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis.Frontiers in pharmacology · 2024Article
- [Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers].The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- The management ofFrontiers in cellular and infection microbiology · 2022Review
- Relationship betweenFrontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.